Abstract
Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.
| Original language | English |
|---|---|
| Pages (from-to) | 120-122 |
| Number of pages | 3 |
| Journal | Experimental and Clinical Transplantation |
| Volume | 13 |
| DOIs | |
| Publication status | Published - Nov 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Deceased donor liver transplantion
- Endstage liver disease
- Hepatitis
- Liver cirrhosis
- Living donor liver transplantion
ASJC Scopus subject areas
- Transplantation
Cite this
Liver transplant outcomes in a newly started program. / Sultanaliev, Tokan; Zhexembayev, Assan; Mukazhanov, Adilbek; Zharkymbekov, Bakhyt; Kuttymuratov, Gani; Spatayev, Zhanat; Ibrayev, Bauyrzhan; Yesmembetov, Kakharman; Ashimkhanova, Aiymkul; Asykbayev, M. Els.
In: Experimental and Clinical Transplantation, Vol. 13, 01.11.2015, p. 120-122.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Liver transplant outcomes in a newly started program
AU - Sultanaliev, Tokan
AU - Zhexembayev, Assan
AU - Mukazhanov, Adilbek
AU - Zharkymbekov, Bakhyt
AU - Kuttymuratov, Gani
AU - Spatayev, Zhanat
AU - Ibrayev, Bauyrzhan
AU - Yesmembetov, Kakharman
AU - Ashimkhanova, Aiymkul
AU - Asykbayev, M. Els
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.
AB - Objectives: Kazakhstan is experiencing a high demand for liver transplants. More than 1000 patients have end-stage liver disease in the country, and liver transplant is the only viable option for their treatment. Materials and Methods: Liver transplant patients, treated from February 2013 to December 2014, were included in this retrospective analysis. Results: From February 2013 to December 2014, seven patients received a liver transplant in our center (1 pediatric patient was excluded). Deceased liver recipients’ (n = 3) median age was 52 years and median Model for End-Stage Liver Disease score 9. The indication for transplant was uncontrolled portal hypertension due to autoimmune liver disease. Cadaveric donors’ median age was 45 years. Recipients’ intensive care unit stay was > 5 days, time on inotropic support was > 3 days. Mean cold ischemic time was > 6 hours, and secondary ischemic time was 67 minutes. One patient in the deceased donor transplant group died during postoperative week 1 from hepatic artery thrombosis. Living donor liver recipients’ (n = 3) median age was 47 years (43-48 y) and median Model for End-Stage Liver Disease score was 17 (range 14-20). Liver disease was hepatitis virus related (hepatitis C virus in 1 patient and hepatitis B and D virus in 2 patients). Mean cold ischemic time was 0.43 hours, and mean secondary ischemic time was 64 minutes. One recipient in the living donor liver group died early in the postoperative period from hemorrhage. Conclusions: Our experience was insufficient to adequately assess morbidity and survival rates in patients for whom the longest follow-up was 25 months. However, no episodes of rejection were observed. Survival rates between living and deceased donor recipients were equivalent, although cadaveric-donor liver conditions were imperfect. This analysis demonstrates the necessity for timely diagnosis of surgical complications, which accounted for all mortality incidence in our series.
KW - Deceased donor liver transplantion
KW - Endstage liver disease
KW - Hepatitis
KW - Liver cirrhosis
KW - Living donor liver transplantion
UR - http://www.scopus.com/inward/record.url?scp=84953851123&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953851123&partnerID=8YFLogxK
U2 - 10.6002/ect.tdtd2015.P66
DO - 10.6002/ect.tdtd2015.P66
M3 - Article
C2 - 26640930
AN - SCOPUS:84953851123
VL - 13
SP - 120
EP - 122
JO - Experimental and Clinical Transplantation
JF - Experimental and Clinical Transplantation
SN - 1304-0855
ER -